RecruitingNCT07226661
SPN-821 added to usual treatment for adult depression
About this title
Read the official source — NCT07226661Medication studyAges 18–70United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
What will I do during this study?
After screening, you take SPN-821 or matching placebo (an inactive comparison treatment) tablets twice a week for four weeks, alongside your current antidepressant. A safety follow-up phone call takes place one week after the treatment period ends.
- Listed locations
- Birmingham and 39 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 19, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 230
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT07226661
- Official title
Show the full official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Birmingham · Phoenix · Rogers
34 more locations
- Chino
- Encino
- Garden Grove
- Lemon Grove
- Montclair
- Orange
- San Jose
- Temecula
- Denver
- Cromwell
- Jacksonville
- Miami
- Orlando
- Palm Bay
- Tampa
- Atlanta
- Decatur
- Warrenville
- Flowood
- O'Fallon
- Saint Charles
- Las Vegas
- Marlton
- Brooklyn
- New York
- Charlotte
- Oklahoma City
- Portland
- Bellaire
- Houston
- Wichita Falls
- Clinton
- Salt Lake City
- Everett
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including SPN-821 2400 mg and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
